# Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers

> **NCT03388216** · PHASE1 · COMPLETED · sponsor: **Inmunova S.A.** · enrollment: 14 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Drug: INM004 Dose 1
- **BIOLOGICAL:** Drug: INM004 Dose 2
- **BIOLOGICAL:** Drug: INM004- Repeated dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03388216
- **Lead sponsor:** Inmunova S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-16
- **Primary completion:** 2018-09-27
- **Final completion:** 2018-09-28
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03388216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03388216, "Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03388216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*